NCT07040657Recruiting
Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometrial Cancer Using Methylene Blue
Comparison of Two-Point and Four-Point Cervical Injection Techniques Using Methylene Blue for Sentinel Lymph Node Mapping in Endometrial Cancer
Source: ClinicalTrials.gov · Last updated 27 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This clinical trial evaluates lymph node mapping in newly diagnosed endometrial cancer patients undergoing surgery. The standard technique uses a 2-point methylene blue cervical injection. The study aims to determine if increasing injection points improves mapping success.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 5 Jun 2025
- Start date
- 1 May 2025
- Primary completion date
- 1 May 2026
- Lead sponsor
- Dokuz Eylul University
- Diseases
- Endometrial cancer
- NCT number
- NCT07040657
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 1 May 2025 to the primary completion date, 1 May 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals who have received active treatment for another malignancy within the past five years.
- Inability to successfully perform PLD (pelvic lymphadenectomy) or history of prior PLD.
Other illness
- Medical Conditions
- Individuals diagnosed with dementia.
- Individuals with allergies to methylene blue or iodine.
- Women with multiple and confluent lymph nodes identified as positive on FDG-PET/CT (such cases are not considered stage I).
- Cancer-Related Conditions
- Individuals with clinically or radiologically identified positive lymph nodes or metastatic disease.
- Individuals with a history of pelvic dissection and/or radiation therapy.
- Individuals with advanced cervical or uterine cancer.
Lab values
- Individuals with hepatic dysfunction and a MELD score ≥ 10 and creatinine ≥ 2·0 mg/dl patients.
Other
- Individuals with T3/T4 lesions.
- Individuals with cervical tumors larger than 2 cm.
- Organ Dysfunction
Who the study is looking for
- Individuals diagnosed with stage I endometrial cancer based on CT and PET-CT imaging.
- Individuals with a pathologically confirmed diagnosis of stage I endometrial cancer.
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ankara University Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Recruiting |
| Dokuz Eylul University Coordinator of this site? Confirm its status | Izmir | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.